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Abstract
Background: PET ligands targeting the translocator protein (TSPO) represent promising tools to visualise
neuroinflammation. Here, we analysed parameters obtained in dynamic and static PET images using the novel
TSPO ligand [18F]GE-180 in patients with relapsing remitting multiple sclerosis (RRMS) and an approach for
semi-quantitative assessment of this disease in clinical routine.
Seventeen dynamic [18F]GE-180 PET scans of RRMS patients were evaluated (90 min). A pseudo-reference
region (PRR) was defined after identification of the least disease-affected brain area by voxel-based
comparison with six healthy controls (HC) and upon exclusion of voxels suspected of being affected in static
60–90 min p.i. images. Standardised uptake value ratios (SUVR) obtained from static images normalised to PRR
were correlated to the distribution volume ratios (DVR) derived from dynamic data with Logan reference
tissue model.
Results: Group comparison with HC revealed white matter and thalamus as most affected regions. Fewest
differences were found in grey matter, and normalisation to frontal cortex (FC) yielded the greatest reduction
in variability of healthy grey and white matter. Hence, FC corrected for affected voxels was chosen as PRR,
leading to time-activity curves of FC which were congruent to HC data (SUV60–90 0.37, U test P = 0.42). SUVR
showed a very strong correlation with DVR (Pearson ρ > 0.9). Focal MS lesions exhibited a high SUVR (range,
1.3–3.2).
Conclusions: This comparison with parameters from dynamic data suggests that SUVR normalised to corrected
frontal cortex as PRR is suitable for the quantification of [18F]GE-180 uptake in lesions and different brain regions of
RRMS patients. This efficient diagnostic protocol based on static [18F]GE-180 PET scans acquired 60–90 min p.i. allows
the semi-quantitative assessment of neuroinflammation in RRMS patients in clinical routine.
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Background
The classic diagnosis of multiple sclerosis (MS) is based
on clinical and paraclinical documentation of the
dissemination of CNS lesions in time and space. Such
lesions and their evolution over time are commonly
detected by magnetic resonance imaging (MRI). This
forms not only the basis of the diagnosis but is also used
to monitor disease activity and inform the decision on
appropriate therapeutic strategies. While in MRI, the
disruption of the blood-brain barrier (BBB) is used as
proxy of disease activity, positron emission tomography
(PET) imaging of activated microglia or macrophages
with the 18-kDa translocator protein (TSPO) visualises
one of the hallmarks of neuroinflammation and thus
might provide a more direct approach to assess disease
activity in MS. TSPO is primarily expressed in activated
microglia, astrocytes, endothelial cells, and infiltrating
macrophages [1] and is therefore associated with ner-
vous system inflammation [2]. The prototypic TSPO
radioligand [11C](R)-PK11195 has been frequently inves-
tigated in various PET imaging studies [3]. However,
quantification with [11C](R)-PK11195 has been shown
to be challenging due to a low free fraction in
plasma, a significant binding to plasma proteins, and
a low extraction fraction in brain with a limited
signal-to-background ratio [4, 5]. This led to the de-
velopment of second-generation TSPO radioligands
with lower non-specific binding and higher affinity
and specificity.
Preclinical data of the third-generation TSPO
radioligand [18F]GE-180 have demonstrated a higher
specific signal in affected brain regions and a lower
non-specific binding in healthy tissue than [11C](R)-
PK11195 in models of stroke [6] and neuroinflamma-
tion [7, 8]. Our own preclinical experience with this
tracer indicated a very good applicability for monitor-
ing neuroinflammatory disease as well [9]. First-in-
human studies with healthy controls (HC) found a
low first-pass extraction resulting in low uptake of
[18F]GE-180 in healthy tissue [10, 11]. Various
compartmental models with and without an extravas-
cular component that takes into account tracer bind-
ing to endothelial cells were investigated and the
authors suggested a two-tissue compartment model
without an extravascular component as the preferred
method for [18F]GE-180 quantification in healthy
controls and 90 min as the optimal scan length for
reliable estimation of volumes of distribution (VT)
[10, 11]. Distribution volumes from Logan plot and semi-
quantitative SUVs (60–90 min p.i.) correlated well with
VT from 2TC model [10, 11]. Although the so far available
pre-clinical data are promising, the performance of
[18F]GE-180 as a tracer for neuroinflammatory diseases in
human patients still needs to be verified.
This is the first study investigating relapsing-remitting
MS (RRMS) patients with [18F]GE-180 PET with the aim
of quantifying the uptake in various anatomical brain re-
gions and in focal lesions. In particular, we focused (1)
on the identification of a pseudo-reference region (PRR),
which is challenging in diseases with widespread inflam-
mation within the brain [12], and (2) on the comparison
of parameters obtained from dynamic and static data,
the latter one avoiding long scan times and demanding
data processing steps, with the goal of providing a
quantification procedure which is suitable for routine
clinical use.
Methods
Radiochemistry
As described previously [13], [18F]GE-180 production
was performed on a FASTLab synthesiser with single-
use disposable cassettes manufactured by GE Healthcare
(The Grove Centre Amersham, UK). Radiochemical purity
exceeded 95% and a high-specific activity was reached, ran-
ging between 2423 and 3293 GBq/μmol.
DNA extraction and polymorphism genotyping
Due to the reported dependency of binding properties of
the second-generation TSPO ligands on a genetic poly-
morphism of the TSPO gene, all individuals were geno-
typed and classified as low-, medium-, or high-affinity
binder (LAB, MAB, and HAB) [14–17]. Genotyping for
TSPO polymorphism was performed at the Department
of Psychiatry of the University Hospital Regensburg on
4 mL whole blood samples. Genomic DNA was ex-
tracted with QIAmp DNA blood maxi kit (Qiagen, Hil-
den, Germany) following the manufacturer’s protocol.
DNA quality assessment was performed with optical ab-
sorbance and gel electrophoresis. Exon 4 of the TSPO
gene containing the polymorphism rs6971 (Ala or Thr
at position 147) as well as exon/intron junctions were
PCR amplified and sequenced using Sanger method with
the primers ex4-F-AGTTGGGCAGTGGGACAG and
ex4-R-GCAGATCCTGCAGAGACGA. Sequencing data
were analysed using SnapGene software (GSL Biotech;
available at snapgene.com). The identified rs6971 geno-
types (C/C, C/T, or T/T) code for the amino acids Ala/
Ala, Ala/Thr, or Thr/Thr at position 147 of the TSPO
protein and were considered to generate a high-,
medium-, or low-affinity binding phenotype, respect-
ively [17].
Patient data and human subjects
Seventeen dynamic PET scans were performed in 14
RRMS patients (7 female and 7male; mean age 39 ± 9 years;
5 MAB and 9 HAB). At the time of the PET scan, 4 pa-
tients were without treatment, 5 patients were receiving
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rituximab, 3 patients were receiving glatirameracetate, 2
were receiving natalizumab, and 1 patient each was
treated with alemtuzumab, interferon-beta, and terifluno-
mide, respectively. The study with patients was approved
by the local ethics committee (IRB no. 601–16) and the
German radiation protection committee. All patients gave
written informed consent.
To determine the most affected brain regions and for
a reproducible definition of reference tissue in MS
patients, a database of 6 healthy controls (HC, 3 female
and 3 male; mean age 23 ± 6 years; 1 MAB and 5 HAB)
was provided by GE Healthcare (The Grove Centre
Amersham, UK). The underlying study of healthy sub-
jects was approved by the McMaster University Research
Ethics Board. Research was conducted in accordance
with the principles of the Declaration of Helsinki and all
subjects gave written informed consent.
Imaging
Dynamic HC PET studies (4 × 30, 3 × 60, 10 × 150,
12 × 300 s) were acquired after injection of 269 ± 7 MBq
[18F]GE-180 on a Biograph 6 PET/CT (Siemens Healthi-
neers, Erlangen, Germany) and reconstructed with
OSEM2D algorithm (8 iterations, 4 subsets, 4 mm Gauss).
Standard corrections for CT-based attenuation, scatter,
decay, and random counts were applied.
Seventeen dynamic PET studies of 14 RRMS patients were
performed on a Biograph 64 PET/CT device (Siemens
Healthineers, Erlangen, Germany). Based on previously pub-
lished experience with HC, a 90-min emission scan was ac-
quired in list mode, starting with injection of 189 ± 11 MBq
[18F]GE-180. Reconstruction with a 256 × 256 × 109 matrix,
voxel size of 1.336 × 1.336 × 2.027 mm3 (framing 12 × 10,
4 × 30, 2 × 60, 2 × 120, 16 × 300 s) was performed using
the same reconstruction settings as for HC data. PET data
were corrected for subject motion within the PMOD Fusion
tool (v3.5, PMOD Technologies, Zurich, Switzerland).
For each subject, a T1-weighted MRI scan with a slice
thickness of at least 3 mm was performed on a Magnetom
3T scanner (Siemens Healthineers, Erlangen, Germany)
with intravenous injection of 0.1 mmol/kg contrast agent
(Gd-BOPTA, MultiHance; Bracco Imaging, Milan, Italy).
Contrast-enhanced (CE) MRI images were co-registered
to the corresponding PET data.
Anatomical brain regions
For VOI-based analysis, anatomical brain regions were
defined with the workflow provided within the PMOD
Neuro tool (v3.5). First, each PET image was mapped to
the corresponding T1-weighted CE MRI image by rigid
matching using the default settings. Then, each MRI
image was normalised to the T1-weighted MRI template
in Montreal Neurological Institute (MNI) space. This
was followed by the application of a maximum
probability atlas (Hammers N30R83 [18]) for VOI defin-
ition. Grey matter was masked by application of the de-
fault threshold of 0.3 on the grey matter probability
atlas. Anatomical brain VOIs were then transformed
into PET space.
Reference tissue extraction
SUV was determined at 60 to 90 min p.i. (SUV60–90)
[11]. For the extraction of brain tissue which is least af-
fected by disease, a voxel-wise comparison of SUV60–90
(two sample t test) between HC and all MS patient scans
was conducted with statistical parametric mapping
(SPM8; Wellcome Trust Centre for Neuroimaging, UK)
assuming unequal variance. Smoothing of images was
not performed. For this purpose, PET data were mapped
into MNI space using the corresponding MRI images
with the PMOD Neuro tool as described in the previous
section. Anatomically defined brain volumes exhibiting a
low fraction of significant voxels in SPM were identified
by determination of the fraction of voxels with a t score
above 2.52 (P < 0.01) for each volume. Within these vol-
umes, the volume best suited for reduction of variability
of healthy tissue uptake was selected by calculating the
coefficients of variation of grey matter (GM) and white
matter (WM) uptake in HC after normalisation to each
eligible brain region.
This was followed by an exclusion of voxels sus-
pected of being affected by disease relying on mean
SUV60–90 and standard deviation (SD) from HC data
in this region. The optimal upper threshold
TPRR = mean + a × SD was iteratively adapted by
minimising the difference between the average PRR
time-activity curve (TAC) of RRMS patients and the
average FC TAC of HC.
Quantification with DVR and SUVR
Specific binding relative to non-displaceable uptake can
be derived directly from compartmental model parame-
ters (binding potential BPND = k3/k4). Alternatively, it
can be calculated from distribution volume ratios
(BPND = VT/VND − 1) [19]. Since there is no reference
tissue available for [18F]GE-180, which is devoid of specific
binding, the quantity of interest was specific binding rela-
tive to healthy tissue PRR (BP = VT/VPRR − 1 = DVR − 1),
which is smaller than BPND = DVR(1 + BPND,PRR) − 1
[20]. The Logan reference tissue model [21] was used to
determine DVR with PMOD Kinetic Modelling tool (v3.4)
from dynamic 20–90 min p.i. data [10]. The population
average rate k2’
REF of the reference tissue was set to 0.027
1/min according to the previously published average value
for frontal cortex k2 estimated with one-tissue compart-
ment model [11]. For one exemplary patient, a parametric
DVR map was generated from dynamic data recon-
structed with a 10-mm Gauss filter. Due to high statistical
Vomacka et al. EJNMMI Research  (2017) 7:89 Page 3 of 9
fluctuations, the coarse filter had to be applied for voxel-
wise fitting with Logan reference tissue model.
To assess whether modelling based on dynamic 20–
90 min p.i. data can be replaced by values obtained from
shorter static scans, a simple quantification based on
standardised uptake value ratios (SUVR = SUV60–90/
SUVPRR,60–90) was carried out by comparison with DVR
obtained from Logan reference tissue model. Correlation
was determined for all brain tissue regions and lesions.
Segmentation of MS lesions
VOIs of 67 focal MS lesions visible in PET were defined
on SUVR images. A delineation method, which aims to
find the boundary reproducing threshold TSUVR based
on the mean signal from 32 hottest voxels of each lesion
(SUVR32Vox, total volume of 0.116 mL) and affected
white matter background (BG) value, was applied [22]:
TSUVR ¼ SUVR32Vox−SUVRBGð Þ  Fþ SUVRBG ð1Þ
The fraction F = 0.35 was derived from a Nema-NU2-
2001 phantom measurement consisting of six hot spheres
in BG (1:8) with different volumes (0.5–26.5 mL). The
affected WM uptake normalised to PRR averaged over all
patients served as BG for the delineation of locally elevated
uptake within WM without being influenced by a patient-
specific lesion load. Alternatively, background volumes sur-
rounding the focal lesions can be delineated manually for
each patient.
Statistical analysis
Results are presented as mean ± SD. Analysis of group-
wise differences between different binding affinity groups
and VOI parameters of HC and MS patient data was cal-
culated with Mann-Whitney U test (U test) using
MATLAB (MathWorks, USA), where P < 0.05 was
considered as a significant difference. Linear correlation
of quantitative parameters was performed (Pearson,
MATLAB, MathWorks, USA).
Results
[18F]GE-180 uptake in MS patients
TAC averaged over all RRMS patient scans are shown in
Fig. 1a. [18F]GE-180 uptake in brain tissue peaked at
about 35 s p.i. with the lowest mean peak-SUV in white
matter (0.88 ± 0.3) and the highest mean peak SUV in
the thalamus (1.24 ± 0.4) and brainstem (1.16 ± 0.4).
Mean peak SUV in cortical and cerebellar grey matter
was similar (1.06 ± 0.4, 1.13 ± 0.4). While cortical and
cerebellar GM reached a plateau after about 60 min p.i,
the brainstem, WM, and also the thalamus of the MS
patients exhibited a slowly increasing TAC after the fast
wash-out. SUV60–90 was lowest in white matter
(0.41 ± 0.05), and highest in brainstem (0.49 ± 0.06) and
thalamus (0.48 ± 0.05). SUV60–90 in cortical GM was
0.43 ± 0.05 and in cerebellar GM 0.44 ± 0.06. In contrast
to the uptake kinetics of apparently not affected tissue,
MS lesions exhibited a constant increase or saturation of
uptake (Fig. 1b) with a mean SUV60–90 of 0.7 ± 0.2.
No significant differences (U test P > 0.05) in SUV60–90
were found between MAB and HAB in all anatomical
brain regions (e.g. combined frontal, temporal, and par-
ietal cortex SUV: MAB = 0.41 ± 0.04, HAB = 0.41 ± 0.05).
Reference tissue extraction
Results from SPM group analysis on static 60 to 90 min
p.i. images are given in Fig. 2. The t score images are
given for a cut-off threshold of P < 0.01. White matter
(average t score 2.7 and P = 0.03) and the thalamus
(average t score 2.6 and P = 0.06) exhibited the highest
fraction of voxels with P < 0.01 (> 55%). The fraction
with P < 0.01 was below 25% in the frontal lobe,
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Fig. 1 [18F]GE-180 time-activity curves in SUV averaged over all MS patient studies. a Mean TAC of brainstem (circle), cortical GM (square), thalamus
(cross), cerebellar GM (diamond), and white matter (triangle). b Mean ± SD TAC averaged over 67 lesions
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temporal lobe, and in cerebellar grey matter (average t
score < 1.8 and P > 0.10). Normalisation to frontal cortex
(FC) led to the lowest variability of grey and white mat-
ter uptake (GM decreased from 12 to 6%, WM remained
at 7%) in HC. Therefore, FC was chosen as the anatom-
ically defined primary reference tissue.
Mean frontal cortex SUV60–90 in HC was 0.37 ± 0.04.
The optimal upper threshold for unaffected FC voxels
obtained by iterative adoption was:
TPRR ¼ meanHC þ 1:7 SDHC ð2Þ
This corresponds to a SUV60–90 threshold of 0.433.
The resulting corrected FC volume applied in the follow-
ing as pseudo-reference region yielded a SUV60–90 of
0.37 ± 0.03 averaged over all MS patient studies. No sig-
nificant difference was found between the corrected
frontal cortex SUV60–90 in MS patients and the corre-
sponding values in HC (Fig. 3, U test P = 0.42). Based
on this pseudo-reference region, SUVR images were
generated as visualised in Fig. 4. Variability in uptake
values in patients reduced with PRR normalisation for
GM from 11 to 7%, and for WM from 13 to 10%.
Quantification with DVR and SUVR
The linear part of the Logan plot started earlier for brain
tissue data than for lesion data and both reached linear-
ity (Fig. 5). DVR derived from Logan reference tissue
model showed a very strong correlation with SUVR
(Fig. 6: anatomical brain regions ρ = 0.97, P < 0.001, and
lesions ρ = 0.93, P < 0.001). In RRMS patients, thalamus
and brainstem exhibited the highest values (SUVR
1.33 ± 0.11 and 1.35 ± 0.17, DVR 1.35 ± 0.14 and
1.45 ± 0.24) and WM and cortical GM the lowest (SUVR
1.11 ± 0.11 and 1.16 ± 0.09, DVR 1.19 ± 0.13 and
1.18 ± 0.10).
For observer-independent assessment of inflammation
activity in focal lesions, a SUVR of 1.3 was assumed as
affected WM background. This value was derived from
SUVR images normalised to PRR by adoption of Eq. (2):
TLesion,BG = meanHC,WM + 1.7 × SDHC, where TLesion,BG
served as lower threshold for the definition of affected
white matter voxels in MS patients. For all RRMS pa-
tients studied, the average SUVR of lesions delineated by
this method was between 1.3 and 3.2 (mean 1.9 ± 0.5).
Maximum SUVR within lesions ranged between 1.5 and
4.9 (2.4 ± 0.9). All MS lesions exhibited an increasing or
saturating TAC (Fig. 1b).
Discussion
This study aimed to provide a robust, clinically suitable
quantification approach for the third-generation TSPO
ligand [18F]GE-180 in MS patients. The investigated
static 60–90 min imaging containing a PRR-based SUVR
quantification correlated well with DVR from modelling
by application of the Logan reference tissue model on
dynamic 90 min and thus proved suitability for clinical
TSPO PET application, when patient compliance and
economic aspects have to be considered. The presence of
non-saturated lesion TACs suggests that a prolongation of
the scan duration, at the cost of a lower count statistic,
might allow for an improved assessment of equilibrium
and tracer wash-out.
Fig. 2 Statistical parametric maps from two sample t test with an extent threshold of 60 voxels with t score values showing differences in [18F]GE-180
uptake in static 60 to 90 min p.i. images between healthy controls and all MS patient scans with a cut-off threshold of P < 0.01 in triangular views
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Fig. 3 Time-activity curves of frontal cortex in healthy controls
(cross), and original frontal cortex (square) and pseudo-reference
region (triangle) averaged over all MS patient scans
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Binding potentials derived with reference modelling
(BP = DVR − 1) reported previously for the prototypic
TSPO ligand [11C](R)-PK11195 in healthy controls, and
MS patients were in a similar range as results presented
here for [18F]GE-180: the lowest BP was found in
normal-appearing white matter and the highest BP in
the thalamus and the brainstem [23–25]. In agreement
with our SPM analysis results, PET signal was signifi-
cantly elevated compared to HC in contrast-enhancing
lesions, thalamus, parts of the brainstem, and in white
matter frequently following white matter fibre tracts
[23, 25–27].
MS lesions exhibited a high [18F]GE-180 uptake and
contrast, enabling a visual detection of focally elevated
tracer accumulations (Fig. 4). The lesion-to-WM-back-
ground ratio (up to a threefold increase in mean lesion
SUVR) appears to be high for [18F]GE-180 compared to
other TSPO radioligands previously used in MS patients
[23–30]. [11C]PK11195 signal in static images normal-
ised to cortical grey matter was significantly higher in
lesions with CE in MRI compared to normal white mat-
ter (up to a factor of 1.4) [26]. For [18F]FEDAA1106,
lesions with CE in MRI were not detectable in SUV and
Logan VT images, probably due to a high non-specific
uptake [30]. Both [18F]PBR111 and [11C]PBR28 showed
an increased VT in some lesions with CE in MRI [24, 28,
29]. However, for [11C]PBR28, static SUV90–120 images
were too noisy for visual detection of MS lesions, most
probably due to the short half-life of 11C in combination
with a high-resolution PET tomograph [29].
The critical aspect for robust and reliable lesion quanti-
fication is the choice of the reference region. It is difficult
to propose a standard reference region for all neurological
diseases since patterns of affection vary widely. In MS, im-
mune cell infiltration is predominantly localised in focal
white matter lesions. However, as the disease progresses,
inflammatory changes spread throughout the CNS and no
region can be assumed to be unaffected. The corrected
frontal cortex seems to be a suitable pseudo-reference
region, at least for RRMS patients, since grey matter was
reported to be less affected than white matter in early
stages of MS [24–26, 28]. In order to identify the least af-
fected regions in RRMS patients, we compared our
patients with a group of young HC, in which no CNS in-
flammation should be present. Although the SPM analysis
revealed a non-negligible fraction (24%) affected by dis-
ease in the frontal cortex, time activity curves were not
significantly different for HC and RRMS patients in this
Fig. 4 Images of an MS patient in native [18F]GE-180 PET space. Top row: T1-weighted contrast-enhanced MRI. Second row: SUV image (60–90 min
p.i.). Third and bottom row: DVR (from dynamic data reconstructed with 10-mm Gauss filter) and SUVR with lower threshold set to 1.0 for the depiction
of specific binding relative to the PRR. a Whole head in triangular views. b Application of brain mask onto parametric maps for two different transaxial
planes with MRI overlay
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region, and it was feasible to exclude suspicious voxels in
this relatively large and well-defined region. The VOI-
based comparison of PRR SUVs with HC data showed
good concordance. Normalisation of PET data by the cor-
rected frontal cortex uptake reduced inter-patient variabil-
ity in grey (from 11 to 7%) and white matter (from 13 to
10%) signals.
Alternative methods recommended for reference tissue
TAC generation of TSPO tracers are data-driven cluster-
ing (DC) [31, 32] or supervised clustering (SC) on dy-
namic data preselected with a brain mask [33, 34]. SC
has been validated for [11C](R)-PK11195 and also tested
for [18F]GE-180 [8]. However, DC and SC require dy-
namic PET studies and previous publications show that
SC might not sufficiently exclude affected voxels in some
cases and that other methods might be superior for the
exclusion of affected voxels [8, 35]. A promising
approach using fixed thresholds for the definition of af-
fected voxels was applied to BP images derived with SC
reference tissue [23] but also needs dynamic imaging.
The reported high inter- and intra-subject variability
found for second-generation radioligands in other stud-
ies was attributed to differences in binding affinity status
and in plasma protein binding [5, 36, 37]. For [11C](R)-
PK11195, in vitro and in vivo data show no significant
differences between binding affinity groups. Unpublished
in vitro work by D. Owen with cold GE-180 displacing
[3H]PK11195 has shown a binding affinity ratio of 15:1
between HABs and MABs [11]. However, Feeney et al.
[11] found no significant differences between MABs and
HABs similar to [11C](R)-PK11195 in healthy brain tis-
sue of human subjects [16]. This is in line with the re-
sults of our current study in which we found no
differences between MAB and HAB. Although in vitro
prediction of differences in specific binding can differ
from the relation observed for in vivo data [15, 38], it is
questionable whether this can explain the results. Such a
discrepancy may be explained by the high dependency of
the in vitro studies on experimental conditions like
temperature, fluid composition, and presence of intact
mitochondria [15]. Furthermore, brain microvascular
endothelial cells change BBB properties in vitro [39]. Fan
et al. [10] suggest that the finding that no differences
could be observed in vivo may be caused by a lower
TSPO affinity of [18F]GE-180 compared to other
second-generation TSPO tracers. Another explanation
proposed by both previous studies is the low brain tissue
uptake [10, 11]. The high fraction of ligand bound to
plasma proteins, probably resulting from a relatively
high lipophilicity (logD at pH 7.4 is 2.95 [40]), may be
the reason for the slow propagation into tissue and the
constantly high activity concentration in blood vessels
dominating signal in healthy tissue (suggesting similar-
ities to [11C](R)-PK11195 in vivo) [41, 42]. Another rea-
son for low uptake in brain may be a fast clearance by
efflux pumps.
Yet, we observe a high contrast in MS lesions and also
in gliomas as published recently [43]. The important
question is what are the underlying processes leading to
this contrast. Does it reflect specific binding to TSPO or
rather other processes like a BBB breakdown? For gli-
omas, we could demonstrate that [18F]GE-180 uptake
patterns do not correlate with contrast enhancement in
T1-weighted MRI images and that even for some gli-
omas, the highest [18F]GE-180 uptake can be found in
non-contrast-enhancing tumour areas [43]. Still one
might hypothesise that those areas exhibit micro BBB
breakdown without apparent enhancement of contrast
agent in MRI [44], which may allow the passage of
[18F]GE-180 through the leaky BBB. However, we also
observe areas with CE in T1-weighted MRI, i.e. with
BBB breakdown, but without elevated [18F]GE-180
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uptake [43]. Even if micro BBB breakdown might ease
the supply of [18F]GE-180, the [18F]GE-180 signal inten-
sity does not correlate with severity of BBB breakdown,
leading to the assumption that the dominant process
resulting in the observed high range of [18F]GE-180
binding should be attributed to TSPO expression levels
rather than mere BBB breakdown. Nevertheless, the lack
of micro BBB breakdown in some regions may lead to
an underestimation of TSPO expression.
One limitation of this study may be the usage of data
from two different PET/CT devices in which the PET
part is identical, but the CT data may yield a slightly dif-
ferent attenuation correction. Also, for future clinical
studies, it would be beneficial to gather a larger database
of HC with varying age to account for age-related changes.
Furthermore, for an encompassing and comprehensive in-
terpretation of the underlying processes, it is indispensable
to perform in vivo blocking studies in combination with
pharmacokinetic modelling with a metabolite corrected
arterial input function and a longer scan duration.
The possibility of static PET imaging provided by the
proposed method in contrast to dynamic PET imaging
will greatly increase the acceptance by patients, as 30-
min scans are usually well-tolerated and the imaging
protocol does not include blood sampling, which is often
perceived as an invasive, displeasing method by patients
and is therefore often avoided in clinical settings. With
these tools, TSPO PET with [18F]GE-180 may enable
straightforward clinical assessment of neuroinflamma-
tory activity in MS beyond the scope of structural MRI
and seems to be a highly promising imaging method
to assess disease activity and therapy response in
RRMS patients.
Conclusions
In patients suffering from RRMS, the new TSPO ligand
[18F]GE-180 presented a highly elevated signal up to a
threefold increase in SUVR of focal lesions compared to
surrounding background. Our data demonstrate a high
correlation between parameters obtained from dynamic
PET imaging with simple SUV ratios extracted from static
60–90 min [18F]GE-180 PET scans using the corrected
frontal cortex as pseudo-reference region.
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